Ablynx names Robert Zeldin CMO

30 November 2015
ablynx-flags-big

Belgian drug developer Ablynx (Euronext Brussels: ABLX) on Monday named Robert Zeldin chief medical officer (CMO) effective December 1.

Dr Zeldin will replace Dr Dominique Tersago.

Dr Edwin Moses, chief executive of Ablynx, said:"We are very pleased that someone with Robert's track record and experience is joining Ablynx as chief medical officer. Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders. His extensive industry experience, including his contribution in obtaining regulatory approval of innovative immunotherapies, will be very important in supporting Ablynx in the development of Nanobody-based therapeutics to address areas of high unmet need."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical